BR112023017472A2 - Processo para a preparação de um inibidor de cyp11a1 e intermediários do mesmo - Google Patents

Processo para a preparação de um inibidor de cyp11a1 e intermediários do mesmo

Info

Publication number
BR112023017472A2
BR112023017472A2 BR112023017472A BR112023017472A BR112023017472A2 BR 112023017472 A2 BR112023017472 A2 BR 112023017472A2 BR 112023017472 A BR112023017472 A BR 112023017472A BR 112023017472 A BR112023017472 A BR 112023017472A BR 112023017472 A2 BR112023017472 A2 BR 112023017472A2
Authority
BR
Brazil
Prior art keywords
cyp11a1
intermediates
inhibitor
methylsulfonyl
pyran
Prior art date
Application number
BR112023017472A
Other languages
English (en)
Inventor
Oskari Karjalainen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of BR112023017472A2 publication Critical patent/BR112023017472A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

processo para a preparação de um inibidor de cyp11a1 e intermediários do mesmo. a presente invenção está relacionada a um processo melhorado para a preparação de inibidores de cyp11a1 estruturados em 4h-piranona, tais como 2-(isoindolin-2-ilmetil)-5-((1-(metilsulfonil)piperidin-4-il)metóxi)-4h-piran-4-ona (1a) e intermediários chave do mesmo, tais como 2-(clorometil)-5-hidróxi-4h-piran-4-ona (ii), 5-hidróxi-2-(isoindolin-2-ilmetil)-4h-piran-4-ona (iii), metanossulfonato de (1-(metilsulfonil)piperidin-4-il)metila (v?) e 4-metilbenzenossulfonato de (1-(metilsulfonil)piperidin-4-il)metila (v). os inibidores de cyp11a1 são úteis no tratamento de cânceres regulados hormonalmente, tal como câncer de próstata e câncer de mama.
BR112023017472A 2021-03-01 2022-02-28 Processo para a preparação de um inibidor de cyp11a1 e intermediários do mesmo BR112023017472A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20215216 2021-03-01
PCT/FI2022/050127 WO2022184975A1 (en) 2021-03-01 2022-02-28 Process for the preparation of a cyp11a1 inhibitor and intermediates thereof

Publications (1)

Publication Number Publication Date
BR112023017472A2 true BR112023017472A2 (pt) 2023-11-07

Family

ID=80685524

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017472A BR112023017472A2 (pt) 2021-03-01 2022-02-28 Processo para a preparação de um inibidor de cyp11a1 e intermediários do mesmo

Country Status (13)

Country Link
US (1) US20240174654A1 (pt)
EP (1) EP4301732A1 (pt)
JP (1) JP2024511295A (pt)
KR (1) KR20230165773A (pt)
CN (1) CN117279893A (pt)
AU (1) AU2022228710A1 (pt)
BR (1) BR112023017472A2 (pt)
CA (1) CA3210591A1 (pt)
CL (1) CL2023002585A1 (pt)
CO (1) CO2023011531A2 (pt)
IL (1) IL305508A (pt)
PE (1) PE20231939A1 (pt)
WO (1) WO2022184975A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426418B1 (en) * 2001-11-02 2002-07-30 Apotex, Inc. Processes for the manufacturing of 3-hydroxy-N,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide
CN101945867A (zh) * 2007-12-19 2011-01-12 安姆根有限公司 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
WO2014164905A1 (en) * 2013-03-12 2014-10-09 Acucela Inc. Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders
AR110412A1 (es) 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1
EP3989966A4 (en) * 2019-06-28 2023-09-27 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF

Also Published As

Publication number Publication date
CO2023011531A2 (es) 2023-11-30
JP2024511295A (ja) 2024-03-13
EP4301732A1 (en) 2024-01-10
CN117279893A (zh) 2023-12-22
AU2022228710A1 (en) 2023-09-07
CL2023002585A1 (es) 2024-02-02
WO2022184975A1 (en) 2022-09-09
KR20230165773A (ko) 2023-12-05
IL305508A (en) 2023-10-01
US20240174654A1 (en) 2024-05-30
CA3210591A1 (en) 2022-09-09
PE20231939A1 (es) 2023-12-05

Similar Documents

Publication Publication Date Title
BR112021023136A2 (pt) Compostos heterocíclicos, métodos de preparação e usos dos mesmos
BR112023017763A2 (pt) Inibidores kras g12d
PE20070427A1 (es) Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
PE20020305A1 (es) 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS COMO INHIBIDORES DE LA TIROSINA QUINASA
BR112013002375A2 (pt) composto, composição farmacêutica, métodos de tratar um indivíduo para um distúrbio proliferativo de induzir a apoptose das células cancerígenas, e de inibir a atividade de cinase em um mamífero, e, processo de preparação de composto
MX2022005780A (es) Moduladores de receptores estrogenicos.
BRPI0510177A (pt) heterociclos monocìclicos como inibidores de cinase
CY1113778T1 (el) Μεθοδος για την παρασκευη αμινοκροτονυλαμινο-υποκατεστημενων παραγωγων της κιναζολινης
MX2013004086A (es) Metodos para inhibir proliferacion celular en cancers accionados por egfr.
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
BRPI0710521A2 (pt) quinazolinas para inibição de pdk1
NO20060091L (no) Anvendelse av kondenserte heterocykliske forbindelser som SCCE-inhibitorer for behandling av hudproblemer eller kreft
CY1123919T1 (el) 1η-βενζιμιδαζολο-4-καρβοξαμιδια υποκατεστημενα με τεταρτοταγη ανθρακα στην 2-θεση ειναι ισχυροι αναστολεις parp
BRPI0518152A (pt) pirazolbenzodiazepinas dissubstituìdas úteis como inibidores para cdk2 e angiogênese e para o tratamento de cánceres de mama, cólon, pulmão e próstata
CL2021003513A1 (es) Compuestos heterocíclicos, como inhibidores de bet; composición, útil para tratar cáncer.
NI201000091A (es) Inhibidores de cinesina como productos terapéuticos para el cáncer.
BR112023017661A2 (pt) Inibidores de kras
UY28177A1 (es) Preparacion de quinazolinas substituidas
SG10201901189SA (en) Substituted piperidine compounds
BR112022002375A2 (pt) Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl
BR112017021636A2 (pt) processo para a preparação de antagonistas de receptor de androgênio e intermediários dos mesmos
BRPI0418765B8 (pt) composto da fórmula (i) e composição farmacêutica
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
BR112023017472A2 (pt) Processo para a preparação de um inibidor de cyp11a1 e intermediários do mesmo
Keramati et al. 7SK small nuclear RNA inhibits cancer cell proliferation through apoptosis induction